IP Library Granted Patent US 12,239,681
Granted Patent B2
US 12,239,681 · App. 18/764,014 · Granted Mar 4, 2025

Formulations and methods for skin care

Inventors: Apostolos Pappas (Norwood, MA); Olga Ilnytska (Norwood, MA)
Assignee: AMILYFE, LLC
A61K36/324A61K8/44A61K8/442A61K8/492A61K8/671A61K8/9789A61K9/00A61K31/07A61K31/11A61K31/198A61K31/203A61K31/232A61K31/405A61K36/32A61K45/06A61K47/24A61K47/38A61Q19/00A61K2800/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,239,681
App. No.
18/764,014
Granted
Mar 4, 2025
Kind
B2
Abstract

Cosmetic and pharmaceutical formulations comprising specific amino acid combinations are described herein. Such formulations strengthen and enhance skin epithelial cell barrier function, thereby reducing moisture loss from the skin and restoring skin's structural integrity, epithelial differentiation, intercellular adhesion, and intracellular signaling and/or promoting maintenance of these features. Additional formulations described here comprise a therapeutically effective amount of free amino acids and a therapeutically effective amount of a plant extract for skin barrier repair. Methods for administering these formulations for cosmetic and/or therapeutic purposes and uses thereof for same are also described herein, including the use thereof in the preparation of medicaments.

Claims (24)

1. A topical formulation, comprising:

(a) as free amino acids, a therapeutically effective amount consisting essentially of a combination of glutamine, glycine, alanine, and serine, or salts thereof,

wherein each free amino acid has a ratio to each of the other free amino acids of: 1:100 or greater; and

(b) a therapeutically effective amount of a plant extract comprising Boswellia extract,

wherein the therapeutically effective amount of the combination and the therapeutically effective amount of the plant extract improve barrier integrity of skin cells when tested by a method detecting EGF expression and determining that EGF is upregulated by a 1.5-40 average fold change of formulation treated as compared to untreated skin,

wherein the therapeutically effective amount of the combination and the therapeutically effective amount of plant extract improve barrier integrity of the skin and/or skin barrier repair.

2. The topical formulation according to claim 1 , wherein each of the free amino acids is present at a concentration of: 0.1 mM or greater; 10 mM or less; or 0.1 mM to 10 mM.

3. The topical formulation according to claim 1 , wherein each of the free amino acids is present at a weight percent to the formulation (wt/wt %) of: 0.001 wt % or greater; 1 wt % or less; or 0.001 wt % to 1 wt %.

4. The topical formulation according to claim 1 , wherein the therapeutically effective amount of the plant extract is present at a weight percentage (w/w %) of the formulation of: 0.025 w/w % or greater; 5 w/w % or less; or 0.025 w/w %-5 w/w %.

5. The topical formulation according to claim 1 , wherein the amino acid combination and the plant extract are in a ratio of: 1:100 or greater; 100:1 or less; or 1:100 to 100:1.

6. The topical formulation according to claim 1 , wherein the plant extract is selected from the group consisting of: Boswellia serrata resin extract, Boswellia serrata extract, olibanum, frankincense, and any combinations thereof.

7. The topical formulation according claim 1 , wherein the therapeutically effective amount of the combination of free amino acids and the therapeutically effective amount of the plant extract inhibit 5-lipoxygenase, decrease mobilization of calcium ions, decrease activation of MAP kinases, or any combination thereof.

8. The topical formulation of claim 1 , further comprising:

a texturing and/or a bulking agent;

a phospholipid;

an anti-caking agent;

a dermatologically acceptable carrier;

additives, or

any combination thereof.

9. The topical formulation of claim 8 , wherein the bulking agent comprises cellulose, microcrystalline cellulose, or combinations thereof.

10. The topical formulation of claim 8 , wherein the phospholipid comprises lecithin, phosphatidylcholine, or combinations thereof.

11. The topical formulation of claim 8 , wherein the anti-caking agent comprises silica.

12. The topical formulation of claim 8 , wherein the additives are selected from the group consisting of: vitamins, minerals, preservatives, desquamation agents, anti-acne agents, anti-wrinkle agents/anti-atrophy agents, hydroxyl acids, anti-oxidants/radical scavengers, chelators, flavonoids, anti-inflammatory agents, anti-cellulite agents, topical anesthetics, tanning agents, skin lightening agents, skin soothing and skin healing agents, antimicrobial and antifungal agents, sunscreen agents, conditioning agents, structuring agents, thickening agents, preservatives and any combinations thereof.

13. The topical formulation according to claim 1 , wherein the free amino acid is in L-form.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2025
From: PAPPAS, APOSTOLOS; ILNYTSKA, OLGA
To: AMILYFE, LLC
Reel/Frame 069755/0178 →
CHANGE OF NAME Recorded Jan 6, 2025
From: ENTRINSIC, LLC
To: AMILYFE, LLC
Reel/Frame 069826/0430 →
CHANGE OF NAME Recorded Nov 19, 2024
From: ENTRINSIC, LLC
To: AMILYFE, LLC
Reel/Frame 069389/0563 →
Continuity (3)
Continuation PCTUS2022082663 · Dec 30, 2022
Provisional Application 63296033 · Jan 3, 2022
Related Publication 20240350571A1 · Oct 24, 2024
References Cited (8)
US 5859208A · Fiddes et al. · 1999 [cited by applicant]
US 20070092461A1 · Gupta · 2007 [cited by applicant]
US 20080050346A1 · Jimenez et al. · 2008 [cited by applicant]
US 20100247563A1 · Hines et al. · 2010 [cited by applicant]
US 20110183040A1 · Ermolin et al. · 2011 [cited by applicant]
US 20120225029A1 · Al-Qahtani · 2012 [cited by applicant]
US 20150299311A1 · Reversade · 2015 [cited by applicant]
US 20210283081A1 · Vidyasagar et al. · 2021 [cited by applicant]